Although HSCT is a viable option for SLE management, its precise clinical utility needs to be further evaluated in well-designed studies.20 Currently, there is one active clinical trial registered on clinicaltrials.gov (NCT05029336) evaluating CD3/CD19-depleted autologous HSCT (Table 1). The gene discussed is CD19; the disease is systemic lupus erythematosus.